-
Biomerica Posts Encouraging Results From InFoods Study As Irritable Bowel Syndrome Treatment
Tuesday, February 8, 2022 - 1:27pm | 308Read More...Biomerica Inc (NASDAQ: BMRA) has announced topline results from its InFoods IBS diagnostic-guided therapy (DGT) endpoint clinical trial. The trial showed statistically significant improvements in multiple endpoints in the Intent-to-Treat population. The InFoods DGT uses a...
-
Citi, Ladenburg React Positively On Ardelyx's IBS-C Treatment Launch Plans
Wednesday, December 1, 2021 - 8:38am | 362Read More...Citigroup raised the price target on Ardelyx Inc (NASDAQ: ARDX) to $13 from $7, with a Buy rating unchanged. The update follows the Company's plans to launch Ibsrela (tenapanor) for irritable bowel syndrome with constipation (IBS-C) independently in Q2 2022....
-
4D Pharma's Stock Shoots Higher on Positive Data from Irritable Bowel Syndrome Candidate
Monday, May 24, 2021 - 9:30am | 360Read More...4D pharma plc (NASDAQ: LBPS) has announced additional positive data from its completed Phase 2 trial of LBP Blautix in subjects with irritable bowel syndrome with constipation (IBS-C) or with diarrhea (IBS-D). The data has been presented at Digestive Disease Week (DDW). The company...
-
Arena Pharma's Olorinab Fails To Top Placebo In IBS-Related Abdominal Pain
Wednesday, March 3, 2021 - 7:10am | 266Read More...Arena Pharmaceuticals Inc (NASDAQ: ARNA) has announced topline data from Phase 2b CAPTIVATE trial evaluating olorinab for abdominal pain due to Irritable Bowel Syndrome (IBS). Although olorinab was well tolerated, the results show that it did not meet the primary...
-
Hoth Therapeutics Plans To Test HT-003 API In Inflammatory Bowel Disorders; Shares Spike
Thursday, February 18, 2021 - 10:27am | 264Read More...Hoth Therapeutics Inc (NASDAQ: HOTH) plans to expand the development of the HT-003 active pharmaceutical ingredient (API) to pursue a new indication for the treatment of inflammatory bowel diseases (IBDs), including Crohn's disease and ulcerative colitis. The company has...
-
Synthetic Biologics Surges 25% Amid Positive Phase 2 Data
Wednesday, January 20, 2016 - 9:22am | 252Read More...Shares of Synthetic Biologics Inc (NYSE: SYN), a clinical-stage biotechnology company, surged higher by 25 percent at $1.90 early Wednesday morning after the company reported positive topline data from a second Phase 2 clinical trial. Synthetic Biologics stated that its second Phase 2 clinical...
